

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HONG KONG HEALTH CHECK AND LABORATORY HOLDINGS COMPANY LIMITED

香港體檢及醫學診斷控股有限公司*

(incorporated in Bermuda with limited liability)

(Stock Code: 397)

PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules.

The Board wishes to inform the shareholders of the Company and potential investors that based on a preliminary estimate, it is expected that the Group will record a significant loss for FY 2008/09 as compared to a profit recorded for the last corresponding year. The principal causes leading to such expected significant loss are set out below.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by Hong Kong Health Check and Laboratory Holdings Company Limited (“**Company**” and, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”).

The board of directors (“**Board**”) of the Company wishes to inform the shareholders of the Company and potential investors that based on a preliminary estimate, it is expected that the Group will record a significant loss for the financial year ended 31 March 2009 (“**FY 2008/09**”) as compared to a profit recorded for the last corresponding year. The Board believes that the principal causes of such expected significant loss are (1) the loss attributable to the holding by a subsidiary and a jointly-controlled entity of the convertible bonds (“**CHI CB**”) issued by Core Healthcare Investment Holdings Limited (“**Core Healthcare**”) (stock code: 8250), a subsidiary of the Company; (2) the diminution in value of the CHI CB which is reflected in the financial statements of the Group; (3) the impairment of goodwill

* For identification purpose only

attributable to Core Healthcare which arose from the securities exchange offer launched by the Company for the shares of Core Healthcare during the FY2008/09; (4); the estimated fair value of share-based payment expense relating to the share options granted by the Company during FY 2008/09; (5) the financial tsunami causing an investment loss, which investment was carried out in accordance with the Group's treasury management policy; and (6) the operating loss caused by the adverse operating environment.

Factors (1), (2), (3) and (4) discussed above are non-cash in nature and will not cause any cash flow burden to the Group. In addition, the effects of factors (1) and (2) are partly off-set by the full redemption of the CHI CB by Core Healthcare on 30 March 2009.

The Board is of the view that the financial position of the Group is solid as it currently does not have any bank borrowings and has a substantial net cash. The Board believes that the Group is well positioned to meet the challenges ahead.

As the Company is still in the process of finalising its unaudited final results for the FY 2008/09 and liaising with an independent valuer to perform a valuation on the share options, this announcement is only a preliminary estimate performed by the management of the Company based on currently available information and is not based on any figures or information audited or reviewed by the Company's auditors. Details of the Company's performance will be disclosed in the final results announcement which is expected to be released by the end of July 2009.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
**Hong Kong Health Check and
Laboratory Holdings Company Limited**
Fung Yiu Tong, Bennet
Chairman

Hong Kong, 13 May 2009

At the date of this announcement, the Board comprises seven executive Directors, namely Dr. Fung Yiu Tong, Bennet, Mr. Lee Chik Yuet, Dr. Cho Kwai Chee, Dr. Hui Ka Wah Ronnie, JP, Mr. Cho Kwai Yee, Kevin, Miss Choi Ka Yee, Crystal and Mr. Siu Kam Chau and three independent non-executive Directors namely Mr. Chan Chi Yuen, Mr. Lo Chun Nga and Mr. Chik Chi Man.